阿托伐他汀治疗慢性阻塞性肺疾病改善肺功能的临床效果分析  

The Clinical Effects of Improving Lung Function for Atorvastatin Treatment of Chronic Obstructive Pulmonary Disease

作　　者：白晓芳[1] 黄天霞[1] 罗艳[1] 林洁[1] 张瓒[1] 

机构地区：[1]广西南宁市第一人民医院,广西南宁530022

出　　处：《现代生物医学进展》2012年第9期1722-1724,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨阿托伐他汀对改善慢性阻塞性肺疾病肺功能的临床效果。方法:60例C0PD患者随机分为对照组组和治疗组各30例,对照组给予常规治疗,治疗组在对照组的基础上口服阿托伐他汀(20mg/d)。两组患者随访12周,比较分析两组患者肺功能改善情况及生活质量的变化情况。结果:两组治疗前肺功能无明显差异,治疗后两组肺功能较治疗前均有显著改善。治疗组较对照组第1秒用力呼气容积(FEVl)、用力肺活量(Fvc)、FEVl/FVC和FEVI占预计值百分比(FEVl%Pred)等明显改善,差异有显著的统计学意义(P<0.01);并且生活质量评分治疗组明显高于对照组,差异有显著的统计学意义(P<0.01)。结论:阿托伐他汀能明显提高慢性阻塞性肺疾病的肺功能,提高患者的生活质量。Objective：To investigate The clinical effects of improving lung function for Atorvastatin treatment of chronic obstructive pulmonary disease.Methods： Sixty C0PD patients were randomly divided into control group and treatment group,30 patients in each group.Control group received conventional therapy,the treatment group were given the oral administration of atorvastatin（20mg / d） based on conventional therapy,Patients were followed up for 12 weeks,And improvement in lung function and quality of life changes in tow groups were compared.Results： There were no significant differences in lung function before treatment in tow groups.Lung function after treatment in two groups were significantly improved.The forced expiratory volume in one second（FEVl）,forced vital capacity（Fvc）,FEVl / FVC and FEVI% predicted（FEVl% Pred） in treatment group were significantly improved than in the control group,the difference was statistically significant（P〈0.01）.And quality of life score was significantly higher than the control group,the dif-ference was statistically significant（P〈0.01）.Conclusions： Atorvastatin can significantly improve lung function and life quality of patients with chronic obstructive pulmonary disease.

关 键 词：慢性阻塞性肺疾病 阿托伐他汀 肺功能 

分 类 号：R563[医药卫生—呼吸系统]